Angion Biomedica (Angion Biomedica) FCF Margin % : 0.00% (As of Mar. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Angion Biomedica's Free Cash Flow for the three months ended in Mar. 2023 was $-8.08 Mil. Angion Biomedica's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, Angion Biomedica's FCF Margin % for the quarter that ended in Mar. 2023 was 0.00%.

As of today, Angion Biomedica's current FCF Yield % is 0.00%.

The historical rank and industry rank for Angion Biomedica's FCF Margin % or its related term are showing as below:

ANGN' s FCF Margin % Range Over the Past 10 Years
Min: -4719.14 Med: 0 Max: 0
Current: -4719.14

ANGN's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -144.01 vs ANGN: -4719.14

Angion Biomedica FCF Margin % Historical Data

The historical data trend for Angion Biomedica's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica FCF Margin % Chart

Angion Biomedica Annual Data

Trend

Dec12

Dec13

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-199.06

-1,669.87

-796.15

-187.29

-1,668.41

Angion Biomedica Quarterly Data
	Jun13	Dec13	Mar14	Jun14	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
FCF Margin %	Get a 7-Day Free Trial															-949.82	-1,516.85	-	-	-

Competitive Comparison of Angion Biomedica's FCF Margin %

For the Biotechnology subindustry, Angion Biomedica's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Angion Biomedica's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Angion Biomedica's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Angion Biomedica's FCF Margin % falls into.

Angion Biomedica FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Angion Biomedica's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-38.39	/	2.301
	=	-1,668.41 %

Angion Biomedica's FCF Margin for the quarter that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2023 )	/	Revenue (Q: Mar. 2023 )
	=	-8.079	/	0
	=	%

Angion Biomedica FCF Margin % Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Angion Biomedica (Angion Biomedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459

Website

https://www.angion.com

Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Executives

Jay Venkatesan	director, officer: See Remarks	C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson	director	601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes	officer: See Remarks	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi	director
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc	10 percent owner	C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553